Samir Mitragotri

rdf:langString Samir Mitragotri

rdf:langString Samir Mitragotri

rdf:langString Samir Mitragotri

rdf:langString Solapur, India

rdf:langString Harvard John A. Paulson School of Engineering and Applied Sciences

rdf:langString Wyss Institute for Biologically Inspired Engineering

rdf:langString Massachusetts Institute of Technology

rdf:langString Institute of Chemical Technology

rdf:langString National Academy of Medicine

rdf:langString Samir Mitragotri (born 28 May 1971 in Solapur, India) is an Indian American professor at Harvard University, an inventor, an entrepreneur, and a researcher in the fields of drug delivery and biomaterials. He is currently the Hiller Professor of Bioengineering and Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences and the Wyss Institute for Biologically Inspired Engineering. Prior to 2017, he was the Duncan and Suzanne Mellichamp Chair Professor at University of California, Santa Barbara. Mitragotri is widely recognized for his contributions to the field of drug delivery. He is considered a pioneer of many novel drug delivery technologies, especially in the fields of transdermal, oral and targeted systems. He invented techniques to deliver drugs transdermally using low-frequency ultrasound, pulsed microjet injector, high throughput skin experimentation, skin penetrating peptides and ionic liquids. He also invented intestinal patches and ionic liquids for oral delivery of proteins. Mitragotri also pioneered nanoparticle-enabled cell therapies which use drug-loaded nanoparticles that hitch a ride on red blood cells, monocytes and other circulatory cells for tissue-specific delivery. Mitragotri's technologies are used to develop next generation therapies against diabetes, cancer, psoriasis, hemorrhage, trauma and infections. Mitragotri has published over 300 research publications, has given over 500 presentations worldwide, and is an inventor on over 180 patents/applications. His publications are cited with an h-index of 102. Mitragotri is a member of the National Academy of Medicine and the National Academy of Inventors. He is also a member of the US National Academy of Engineering in 2015 for the development, clinical translation, and commercialization of transdermal drug delivery systems. He is a co-founder of several companies that are developing products based on his inventions. He received his PhD in chemical engineering at MIT and BS in chemical engineering from the Institute of Chemical Technology. Mitragotri serves on the editorial boards of several journals and currently serves as editor-in-chief of Bioengineering and Translational Medicine.

rdf:langString Robert S. Langer, Daniel Blankschtein